Cost-Effectiveness Of Combined Treatment With Alteplase (Rt-Pa) And Cerebrolysin In Acute Ischemic Hemispheric Stroke In Austria.

Dr. Evelyn Walter IPF Institute for Pharmaeconomic Research Wolfengasse 4/7 1010 Vienna, Austria Tel +43-1-5132007-13 Fax +43-1-5132007-15 Email: [email protected] Web: www.ipf-ac.at Objectives Worldwide, stroke is the third most common cause of death in developed countries with declining death rates. In Austria the incidence rate of stroke is 2.1 – 2.3 per thousand annually. Cerebrolysin prevents acute neuronal damage and accelerates recovery after stroke. The purpose of this analysis was to determine costs of stroke for Austria in general and to estimate the cost-effectiveness of Cerebrolysin in combination with alteplase compared to alteplase alone. The analysis should assess health economic advantages in the acute care due to a faster improvement in neurological impairment and for rehabilitation in early post-acute phase and quantify the correlated reduced resource use in the health care and social system.